載入...
HLJ2 Effectively Ameliorates Colitis-Associated Cancer via Inhibition of NF-κB and Epithelial–Mesenchymal Transition
INTRODUCTION: Colitis-associated cancer (CAC) accounts for approximately 15% of IBD patient mortalities. However, currently available anti-CAC drugs possess many disadvantages including safety, specificity and side effects. Therefore, the development of novel anti-CAC compounds is imperative. HLJ2 w...
Na minha lista:
| 發表在: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7573331/ https://ncbi.nlm.nih.gov/pubmed/33116416 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S262806 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|